288 related articles for article (PubMed ID: 30565155)
1. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
[TBL] [Abstract][Full Text] [Related]
2. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y
Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Uchiyama S; Ishizuka N; Shimada K; Teramoto T; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Minematsu K; Matsumoto M; Ikeda Y;
Stroke; 2016 Jun; 47(6):1605-11. PubMed ID: 27165949
[TBL] [Abstract][Full Text] [Related]
5. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Jones WS; Mulder H; Wruck LM; Pencina MJ; Kripalani S; Muñoz D; Crenshaw DL; Effron MB; Re RN; Gupta K; Anderson RD; Pepine CJ; Handberg EM; Manning BR; Jain SK; Girotra S; Riley D; DeWalt DA; Whittle J; Goldberg YH; Roger VL; Hess R; Benziger CP; Farrehi P; Zhou L; Ford DE; Haynes K; VanWormer JJ; Knowlton KU; Kraschnewski JL; Polonsky TS; Fintel DJ; Ahmad FS; McClay JC; Campbell JR; Bell DS; Fonarow GC; Bradley SM; Paranjape A; Roe MT; Robertson HR; Curtis LH; Sharlow AG; Berdan LG; Hammill BG; Harris DF; Qualls LG; Marquis-Gravel G; Modrow MF; Marcus GM; Carton TW; Nauman E; Waitman LR; Kho AN; Shenkman EA; McTigue KM; Kaushal R; Masoudi FA; Antman EM; Davidson DR; Edgley K; Merritt JG; Brown LS; Zemon DN; McCormick TE; Alikhaani JD; Gregoire KC; Rothman RL; Harrington RA; Hernandez AF;
N Engl J Med; 2021 May; 384(21):1981-1990. PubMed ID: 33999548
[TBL] [Abstract][Full Text] [Related]
9. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
[TBL] [Abstract][Full Text] [Related]
10. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Sleem A; Effron MB; Stebbins A; Wruck LM; Marquis-Gravel G; Muñoz D; Re RN; Gupta K; Pepine CJ; Jain SK; Girotra S; Whittle J; Benziger CP; Farrehi PM; Knowlton KU; Polonsky TS; Roe MT; Rothman RL; Harrington RA; Jones WS; Hernandez AF
JAMA Cardiol; 2023 Nov; 8(11):1061-1069. PubMed ID: 37792369
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Zuo FT; Liu H; Wu HJ; Su N; Liu JQ; Dong AQ
Medicine (Baltimore); 2017 Jan; 96(1):e5497. PubMed ID: 28072691
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
15. Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Ando K; Shimada K; Yamazaki T; Uchiyama S; Uemura Y; Ishizuka N; Teramoto T; Oikawa S; Sugawara M; Murata M; Yokoyama K; Ikeda Y;
J Hypertens; 2019 Jun; 37(6):1301-1307. PubMed ID: 31022110
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Johnston SC; Easton JD; Farrant M; Barsan W; Conwit RA; Elm JJ; Kim AS; Lindblad AS; Palesch YY;
N Engl J Med; 2018 Jul; 379(3):215-225. PubMed ID: 29766750
[TBL] [Abstract][Full Text] [Related]
19. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Steinhubl SR; Bhatt DL; Brennan DM; Montalescot G; Hankey GJ; Eikelboom JW; Berger PB; Topol EJ;
Ann Intern Med; 2009 Mar; 150(6):379-86. PubMed ID: 19293071
[TBL] [Abstract][Full Text] [Related]
20. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]